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Discriminating subjects at clinical high risk (CHR) for 
psychosis who will develop psychosis from those who will 
not is a prerequisite for preventive treatments. However, it 
is not yet possible to make any personalized prediction of 
psychosis onset relying only on the initial clinical baseline 
assessment. Here, we first present a systematic review of 
prognostic accuracy parameters of predictive modeling 
studies using clinical, biological, neurocognitive, environ-
mental, and combinations of predictors. In a second step, we 
performed statistical simulations to test different probabi-
listic sequential 3-stage testing strategies aimed at improv-
ing prognostic accuracy on top of the clinical baseline 
assessment. The systematic review revealed that the best 
environmental predictive model yielded a modest positive 
predictive value (PPV) (63%). Conversely, the best predic-
tive models in other domains (clinical, biological, neurocog-
nitive, and combined models) yielded PPVs of above 82%. 
Using only data from validated models, 3-stage simulations 
showed that the highest PPV was achieved by sequentially 
using a combined (clinical + electroencephalography), then 
structural magnetic resonance imaging and then a blood 
markers model. Specifically, PPV was estimated to be 98% 
(number needed to treat, NNT = 2) for an individual with 
3 positive sequential tests, 71%–82% (NNT  =  3) with 2 
positive tests, 12%–21% (NNT  =  11–18) with 1 positive 
test, and 1% (NNT = 219) for an individual with no positive 
tests. This work suggests that sequentially testing CHR 
subjects with predictive models across multiple domains 
may substantially improve psychosis prediction following 
the initial CHR assessment. Multistage sequential testing 
may allow individual risk stratification of CHR individuals 
and optimize the prediction of psychosis.
Key words: psychosis/clinical high-risk/prediction/prognostic 
accuracy/treatment prognosis/early interventions
Introduction
In the last 2 decades, a new research paradigm has sup-
ported the development of preventive interventions in 
individuals at clinical high risk (CHR) for psychosis.1 
Preventive intervention in CHR individuals for psychosis 
has unique and unprecedented potential in the history of 
psychiatry to alter the course of disabling illnesses such 
as schizophrenia (see meta-analyses of effective treat-
ments in CHR individuals2,3).
Effective preventive interventions for CHR indi-
viduals are limited by the ability to prognosticate 
psychosis onset from an initial CHR state. CHR psy-
chometric instruments have excellent prognostic prop-
erties (AUC  =  0.90),4 which is comparable to other 
preventive approaches in medicine.5 However, excel-
lent prognostic performances are mainly mediated by 
an outstanding ability of  the CHR instruments to rule 
out psychosis, ie, very low negative likelihood ratios 
and high sensitivity (SE), at an expense of  their abil-
ity to rule in psychosis, ie, unsatisfactorily low positive 
likelihood ratios and only moderate overall specificity 
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(SP).4 Specifically, the initial CHR testing can increase 
the probability of  detecting risk of  developing psy-
chosis in subjects referred to high-risk services from 
15% (pre-test risk) at approximately 3 years4 to a 26% 
probability of  psychosis onset (post-test risk),4 mostly 
toward schizophrenia spectrum psychoses6 (for further 
details on pre- and post-test concepts please see Fusar-
Poli et  al7,8). Consequently, there is a need to improve 
the ability to rule in heightened risk of  subsequent psy-
chosis, while preserving the outstanding ability to rule 
it out.4 Improved prediction would facilitate personal-
ized interventions and minimize either unnecessary 
treatment (for the false positives) or lack of  treatment 
(for the false negatives). To improve the limited positive 
predictive values (PPVs) delivered by psychopathology-
based classifications associated with CHR instruments,9 
models with biological, neurocognitive or environmen-
tal data have been developed. In fact, the use of  predic-
tive models10 along with sequential multistage testing11 
is common practice in preventive medicine to improve 
prognostic discrimination between individuals who will 
develop a certain condition and those who will not.
This study first presents a systematic review of predic-
tive models used to improve prediction of psychosis onset 
in CHR. We systematically reviewed prognostic accuracy 
metrics (SE, SP, PPV, negative predictive value (NPV), 
for details see Fusar-Poli et  al7) across clinical, biologi-
cal, neurocognitive, environmental, and combined pre-
dictive models. In a second step, we sought to investigate 
the potential clinical utility of sequential 3-stage testing 
following an initial CHR assessment. We employed meta-
analytical simulation analyses across different combina-
tions of models and critically discussed the findings in 
light of risk stratification approaches.12
Methods
Search Strategy and Selection Criteria
A systematic search strategy identified relevant articles. 
Three investigators (MC, GR, AS) conducted a 2-step 
literature search. At a first step, the Web of Knowledge 
database by Thomson Reuters was searched, incorporat-
ing both the Web of Science and MEDLINE. The search 
was extended until October 2015. We used several combi-
nations of the following keywords: “at risk mental state,” 
“psychosis risk,” “prodrome,” “prodromal psychosis,” 
“high risk,” “prognostic accuracy,” “sensitivity,” “speci-
ficity,” “psychosis prediction,” “psychosis onset,” and the 
name of each CHR assessment instrument. The second 
step involved using Scopus to search citations of previ-
ous systematic reviews on transition outcomes in CHR 
subjects and a manually searching the reference lists of 
retrieved articles. Articles identified through these 2 steps 
were then screened for the selection criteria on basis of 
abstract. The articles with potentially relevant abstracts 
were retrieved and assessed for eligibility.
Studies were included if  the following criteria were 
fulfilled: (a) original articles, written in English; (b) 
inclusion of CHR subjects (ie, presence of attenuated 
psychosis symptoms [APS] or genetic risk and deteriora-
tion syndrome [GRD] or brief  limited and intermittent 
psychotic symptoms [BLIPS] or brief  intermittent psy-
chosis syndrome [BIPS] or basic symptoms) according to 
international standard criteria1; (c) inclusion of clinical, 
biological, neurocognitive, environmental, or combina-
tions of predictors to distinguish CHR individuals who 
later developed psychosis from those who did not; (d) 
inclusion of appropriate predictive models, algorithms, 
or learning systems to predict the probability of transi-
tion to psychosis, such as regression (logistic, Cox pro-
portional hazard model, least absolute shrinkage, and 
selection operator), support vector machines or greedy 
algorithms.13–16 Exclusion criteria were: (a) abstracts, 
pilot datasets, reviews, articles in languages other than 
English; (b) inappropriate statistics (ie, use of mean dif-
ferences or chi square tests); (c) studies testing the prog-
nostic accuracy of the baseline CHR assessment as 
predictor (previously reviewed in Fusar-Poli et  al4) (d) 
articles with overlapping datasets using the same predic-
tor. Specifically, in case of multiple publications deriving 
from the same study population, we selected the articles 
reporting the largest, most recent data set. The search 
results were summarized according to the PRISMA 
guidelines17 (figure 1).
Recorded Variables
Data extraction was independently performed by 3 inves-
tigators (MC, GR, AS). The following variables were 
recorded from each article: author, year of publication, 
demographic characteristics of the CHR sample, predic-
tor domain (clinical, biological, neurocognitive, environ-
mental, combinations), cut-off  of predictive variables, 
use of validation, type of CHR diagnostic instrument 
used, exposure to antipsychotics, follow-up time, predic-
tive model and prognostic accuracy data (SE, SP, PPV, 
NPV). When prognostic accuracy data were not directly 
presented they were indirectly extracted from associated 
measures if  possible. Additionally, we contacted all the 
corresponding authors to provide additional data when 
needed.
Meta-analytical Sequential Testing Simulations
Models Selection. Using statistical probabilistic simula-
tions based on Bayes’theorem,18 we estimated the theoreti-
cal PPV of a sequential 3-stage testing following the initial 
CHR assessment. Such testing included different combina-
tions of 3 predictive models (eg, electroencephalography/
clinical, magnetic resonance imaging, and blood mark-
ers). We restricted the simulations to 3 tests because more 
tests would be practically infeasible in clinical practice. 
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Validation is of paramount importance if the estimation 
of the PPV has to work satisfactorily for individuals other 
than those from whose data the model was derived.19,20 
Therefore, we limited the potential combinations of tests 
to studies that had performed a validation of their models. 
Also, we did not mix together models that used the same 
type of predictive parameters, eg, we did not simulate com-
binations in which 2 of the assessments involved EEG.
Procedure. See online supplementary methods 1 for 
mathematical details of these analyses, which were con-
ducted using R software.21 Briefly, we simulated that an 
individual would first have a CHR baseline assessment, 
which would convert the “pre-CHR assessment prob-
ability of transition to psychosis” into a “post-CHR 
assessment probability of transition to psychosis”.7 The 
value of the latter would depend on the former, on the 
SE and SP of the CHR assessment, and on the result of 
the CHR assessment.4 If  the CHR assessment was posi-
tive, the individual would then undergo a second test (eg, 
a structural MRI) which would convert the “post-CHR 
assessment/pre-MRI probability of transition to psycho-
sis” into a “post-MRI probability of transition to psy-
chosis.” Again, the value of the latter would depend on 
the former, on the SE and SP of the MRI test, and on the 
result of the MRI assessment. These steps were repeated 
for each of the 3-stage tests.
Following this strategy, we obtained probabilistic 
3-stage sequential testing diagrams such as the one shown 
in figure 2, in which the x-axis shows the sequential tests 
and the y-axis the probability of transition to psychosis 
before and after knowing the results of each of the tests. 
Each bifurcation in the plot represents the update in the 
probability of transition to psychosis after knowing that 
the test yielded a positive result (ascending solid line) 
or after knowing that the test yielded a negative result 
(descending dashed line).
We focused on the combination that yielded the best 
PPV, as this would be the one to be further validated and 
potentially applied in clinical practice4 (see online supple-
mentary methods 2 for details). However, in order to pro-
vide the whole range of results from this simulation work, 
we also present the following less advantageous scenarios.
Firstly, we reported the poorer global PPVs of all other 
combinations of tests. Secondly, we estimated the lower 
limit of the 95% confidence interval of the global PPV. 
This global interval combined the confidence interval of 
the pre-CHR assessment probability to transition,4 plus 
the 4 confidence intervals associated to the CHR assess-
ment and the 3 subsequent tests.
Fig. 1. PRISMA flow chart.
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Thirdly, we recalculated the global PPV assuming a 
degree of correlation between the tests, so that the SE and 
SP of a test would depend on the results of the previous 
tests, decreasing the contribution of the test to the global 
PPV. For example, we assumed that among individuals 
who will have a psychotic episode, those with a positive 
CHR assessment are more likely to have a positive MRI 
test.
Impact of CHR Subgroups. Finally, we repeated the 
simulation for different CHR subgroups. Given that 
the BLIPS/BIPS shows the highest risk of transition to 
psychosis, which is comparable to other brief  psychotic 
disorders coded in international manuals,25 the GRD the 
lowest risk and the APS an intermediate risk,26 we con-
ducted a separate analysis to test the impact of the CHR 
subgroup on the final prognostic accuracy.
Theoretical Clinical Effectiveness of 3-Stage Sequential 
Testing. We further assessed the theoretical clinical 
effectiveness of 3-stage sequential testing by estimating 
the number needed to treat (NNT) at each node, assum-
ing a risk ratio for preventative treatments of 0.54 as 
reported in previous meta-analysis of RCTs in CHR 
patients.3
Results
Selection of Studies
The electronic and manual searches returned 1300 stud-
ies. After the screening of abstracts 112 full articles were 
retrieved for further evaluation (figure 1). Twenty-five of 
them met the inclusion criteria; 10 studies using clinical 
predictive models, 5 studies using biological models, 5 
studies using neurocognitive models, 5 studies using envi-
ronmental models, and 8 studies using combinations of 
predictive models across different domains. The details of 
the included studies are reported in table 1.
Clinical Predictive Models
The 10 studies testing prognostic accuracy of clinical 
predictive models are shown in table  2. These tested a 
wide range of clinical parameters including specific posi-
tive,27,31,32,38,40,42,46,48 negative27,32,38 and basic symptoms,40 a 
decline in social and global functioning27,31,36,46 and the 
Strauss and Carpenter Prognostic Scale.37
The highest PPV of 86% was achieved by using a model 
including measures of odd beliefs, marked impairment in 
role functioning, blunted affect, auditory hallucinations, 
and anhedonia/asociality.27 This model yielded an SE of 
Fig. 2. Probabilistic risk assessment diagram illustrating the 3-stage sequential testing of the best combination of complementary 
tests identified by our simulation analyses: step 1: EEG + clinical test,22 step 2: structural MRI test,23 and step 3: blood markers test.24 
The x-axis shows the 3 sequential tests following the initial clinical high-risk assessment and the y-axis the probability of transition to 
psychosis during 36 months of follow-up, before and after knowing the results of each test. Each bifurcation in the plot represents the 
update in the probability of transition to psychosis after knowing that the test yielded a positive result (ascending solid line) or after 
knowing that the test yielded a negative result (descending dashed line). The color of the lines reflects the level of risk for psychosis as 
previously suggested18: high (in red) when the probability of transition to psychosis (PT) was >80%, medium when PT was 20%–80% and 
low (in green) when PT was <20%; we further subdivided medium in medium-high (in orange, when PT was between 70% and 80%) and 
medium-low (in brown, when PT was 20%–30%). The diagram also illustrates the number needed to treat (NNT) at each node.
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84%, SP of 86%, and NPV of 84%. None of the clinical 
predictive models have been validated.
Biological Predictive Models
Five studies tested the prognostic accuracy of biological 
predictive models (table 2). The tested models referred to 
measures of gray matter volume,23 electrophysiological 
markers,39,44,47 and blood analytes.24
The highest PPV of 83% was achieved using gray matter 
volumes as the predictive variable, which produced an SE 
of 76%, SP of 85%, and NPV of 78%.23 This23 and 2 other 
biological predictive models24,47 have been cross-validated.
Neurocognitive Predictive Models
Five studies tested the prognostic accuracy of cognitive 
predictive models (table 2). Cognitive predictive models 
included measurements of IQ,30,32,40 verbal memory,30,35 
executive functioning,35 attention,32 processing speed,30,35 
and speech perception.29
Including verbal and executive functioning in the pre-
dictive model, the highest PPV of 83% could be achieved 
accompanied with an SE of 75%, SP of 80%, and NPV of 
71%.35 Only this model35 has been validated in this domain.
Environmental Predictive Models
The prognostic accuracy of environmental predictive 
models was tested in 5 studies (table  2). These predic-
tive models comprised substance abuse,31,43 unemploy-
ment,33 urbanicity,34 social-sexual aspects,34 and social 
maladjustments.34,38
The highest PPV (63%) was produced by combining 
measures of urbanicity, social-sexual aspects, and social-
personal adjustment, a predictive model that revealed an 
SE value of 63%, SP of 88%, and NPV of 88%.34 None of 
the environmental predictive models have been validated.
Combinations of Predictive Models
Eight studies combined different predictive models across 
domains to test prognostic accuracy (table 2). These stud-
ies combined variables from 2 of the predictive models 
domains,22,28,31,32,38,40,41,45 but no study considered variables 
from 3 domains.
The highest PPV (82%) resulted from a predictive model 
including disorganized communication, suspiciousness, 
verbal memory deficit, and decline in social functioning. 
This predictive model yielded an SE of 60%, SP of 97%, 
and NPV of 93%.45 Excluding this predictive model, 3 other 
combined predictive models22,32,41 have been validated.
Validated Models Used in the Sequential Testing 
Simulations
Seven models with validation procedures were used for 
the simulations.22–24,32,35,41,47 Model details are reported in 
table 3.
Meta-analytical Sequential Testing Simulations
We conducted 13 simulations in total, the details of 
which are reported in online supplementary figure 1. The 
highest PPV was achieved by sequentially using a com-
bined model (clinical + EEG22) and 2 biological (struc-
tural MRI23 and blood markers24) models (figure  2). 
Specifically, PPV was estimated to be 98% for an individ-
ual with 3 positive tests, 71–82% for an individual with 2 
positive complementary tests, 12%–21% for an individual 
with 1 positive complementary test, and 1% for an indi-
vidual with no positive tests (figure 2). Accordingly, the 
NNT was 2 for those with 3 positive sequential tests, 3 for 
those with 2 positive tests, 11–18 for those with 1 positive 
test, and 219 for those with no positive tests (see online 
supplementary table 1 for results in the bounds of the CI 
of the risk ratio for preventive treatments). This suggests 
that 3-stage sequential testing can significantly impact 
effectiveness of preventative treatments in CHR samples. 
To demonstrate the worst case scenario, we additionally 
used the lower limit of the confidence interval, producing 
lower but still medium PPVs: 49% for an individual with 
3 positive tests, and 24%–30% for an individual with 2 
positive tests (see online supplementary figure 2). PPVs 
after assuming the strongest possible correlation between 
the tests yielded high (or medium to high) PPVs: 98% 
for an individual with 3 positive tests, and 55%–81% for 
an individual 2 positive complementary tests (see online 
supplementary figure 3).
PPVs were similar when the analysis was restricted to 
CHR individuals meeting APS criteria at baseline (high 
for 2 or 3 positive tests and low otherwise), but globally 
higher when the analysis was restricted to CHR individu-
als meeting BLIPS/BIPS criteria (high for 2 or 3 positive 
tests, still medium for 1 positive test, and low otherwise), 
and globally lower when the analysis was restricted 
to CHR individuals meeting GRD criteria (high for 3 
positive tests but medium for 2 positive tests, and low 
otherwise) (see online supplementary table 2 and supple-
mentary figure 4).
Discussion
To our knowledge, this is the first study to systematically 
review predictive models for psychosis onset in CHR and 
to test the theoretical clinical utility of a 3-stage sequen-
tial testing to improve psychosis prediction. Twenty-five 
original studies were retrieved, addressing clinical, bio-
logical, neurocognitive, environmental, or combinations 
of predictive models across different domains. The high-
est PPV across environmental predictive models was 
modest (63%),34 whereas the highest PPVs in clinical,27 
biological,23 neurocognitive,35 and combined45 predictive 
models were above 82%. Thirteen 3-stage sequential test-
ing simulations based on probabilistic risk assessment 
were conducted. The best model showed that probability 
of transition in a CHR individual was 98% if  the 3 tests 
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were positive based on 1 combined (EEG + clinical)22 
and 2 biological predictive models (structural MRI and 
blood markers),23,24 71%–82% if  only 2 tests were posi-
tive, 1%–21% with 1 positive test, and 1% with no positive 
sequential tests.
We focused on PPV to improve risk prediction in CHR 
samples. This is based on the findings of our previous 
work which indicated that CHR instruments have excel-
lent prognostic accuracy to rule out true negatives, sub-
jects who not go on to develop psychosis.4 By contrast, 
there is still a need to specifically improve the ability to 
rule in subsequent psychosis and to increase PPVs.4 We 
examined 25 studies encompassing different types of 
biological, neurocognitive, environmental, and com-
bined predictive models. The environmental predictive 
models yielded modest PPVs (63% for the best model34). 
This may reflect a poor discriminative power that may 
be caused by heterogeneity in the environmental factors 
entered in the models. Environmental predictive models 
were mostly based on general factors associated with 
psychotic disorders such as substance abuse,31,43 urban-
icity,34 unemployment,33 and social maladjustment34,38 so 
it is plausible that their specificity to CHR pathophysi-
ology is relatively poor. These models were also char-
acterized by poor methodological quality as none had 
employed validation analyses to confirm their findings. 
Conversely, the models from the other domains (clini-
cal, neurobiological, neurocognitive, combination) with 
the highest PPVs had values above 82%. An additional 
finding is that of nonsuperiority of combined predictive 
models (82% for the model delivering the highest PPV45) 
as compared to the other models such as neurocognitive 
models (83% the highest PPV35). Similar findings have 
been observed for dementia prediction in patients with 
mild cognitive impairment where the accuracy of com-
bined models (neuropsychological testing, health screen-
ing, neuroimaging, genetics, and informant or patient 
reports) did not significantly exceed that of more parsi-
monious models.49 A previous study by our group found 
that combining cognitive, genetic, and imaging methods 
did not substantially improve the discrimination between 
healthy controls and CHR individuals.50 Therefore, here 
we simulated the potential clinical utility of a 3-stage 
sequential probabilistic testing to refine psychosis predic-
tion. Probabilistic testing analyses are common in other 
areas of preventative clinical medicine. For instance, they 
have been successfully applied to discriminate patients 
with Alzheimer’s disease from other forms of dementia.51
Because our 3-stage sequential testing analysis is not 
based on original data but on statistical simulations, we 
have restricted it only to the validated predictive models. 
Measures of prognostic accuracy are extremely sensitive 
to the design of the study and studies without validation 
procedures can severely overestimate the indicators of test 
performance. Overall, only 7 studies included in the cur-
rent review have employed a rigorous prognostic accuracy 
approach combining appropriate predictive modeling with 
internal validation. Importantly, from the models with the 
highest PPVs, only the biological23 and neurocognitive35 but 
not the combined model45 underwent validation. We thus 
tested if PPV could be improved on top of the initial CHR 
baseline assessment4 by sequentially combining 3 validated 
predictive models in 13 different combinations (see online 
supplementary figure 1). Our probabilistic testing simula-
tions identified the best theoretical model, which was based 
on 1 combinatory (EEG + clinical)22 and 2 biological pre-
dictive models (structural MRI36 and blood markers23,24) 
(figure 2). This model showed that at least 3 positive tests 
are required to reach a high PPV for the development of 
psychosis (98%) and 2 negative tests to have low probability 
(1%–21%). These findings provide a theoretical framework 
suggesting that sequential testing in CHR individuals may 
improve psychosis prediction by stratifying individual risk 
profiles. It is striking that all 3 predictive model tests that 
were used in the meta-analytical probabilistic assessment 
included biological measurements. It may be speculated 
that since biological predictors of psychosis map direct 
neurobiological processes associated with the develop-
ment of the illness, they have a high PPV. The first model 
in our simulation includes clinical variables (premorbid 
functioning) together with the P300 event-related poten-
tial.22 Interesting in this context is the fact that a recent 
meta-analysis confirmed that event-related potentials such 
as the P300 or the mismatch negativity (a measure of pre-
diction error dependent learning52) may be used as promis-
ing markers to predict the onset of psychosis.53 The second 
test in our simulation includes gray matter volume reduc-
tions in prefrontal cortices such as dorso- and ventromedial 
areas as well as the cingulate cortex, which have been widely 
implicated in CHR pathophysiology,23 and are known to be 
involved in cognitive processing.54 Impairments in cognitive 
performance are associated with the onset of psychosis and 
may be useful in predicting psychosis.55,56 Finally, our third 
test includes a multiplex blood assay.24 Most of the blood 
analytes were involved in the regulation of the hypotha-
lamic-pituitary axis, oxidative stress and inflammation, all 
of which are abnormal in patients with schizophrenia.57–60 
Consistent with the hypothesis that inflammation, oxidative 
stress, and dysregulation of hypothalamic-pituitary axes 
may be prominent in the earliest stages of psychosis,24 CHR 
subjects had elevated cortisol levels and increased hypo-
thalamic61 and pituitary volumes.62 Overall, our findings 
indicate that measures of pathophysiological anomalies 
may complement baseline clinical assessments to stratify 
CHR individuals into different risk groups, which in turn 
may lead to personalized treatments to prevent transition 
to psychosis.12 In a first sensitivity-preserving step, CHR 
psychometric instruments could be used to rule out sub-
jects seeking help at high-risk services but who are unlikely 
to develop psychosis. In a second step, additional tests of 
objective pathophysiological measures could be sequen-
tially applied to the CHR group, with the aim of increasing 
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prognostic reliability. Multicomponent sequential testing 
will not only decrease the risk of offering unnecessary treat-
ment to false positives, but may also inform the treatment 
for people who do go on to develop psychosis. This could 
improve the benefits associated with early detection and 
early intervention, while reducing the possible costs (eg, 
weight gain) associated with receiving unnecessary phar-
macological treatment.
Limitations and Future Directions
Our sequential testing is theoretical and not based on 
original data. Future original investigations should test 
the generalizability of our approach. Collaborative stud-
ies between international multisite CHR projects such as 
PRONIA (www.pronia.eu/), PSYSCAN (www.psyscan.
eu/) and NAPLS3 (http://campuspress.yale.edu/napls/) 
are being planned and they may deliver large scale data-
bases needed to externally validate the stepwise assess-
ment identified by the current analysis. Another issue that 
may have influenced our simulation results may be the 
presence of affective comorbidities that can impact both 
psychopathology63 and neurobiology64 of a CHR sample. 
There were no data to test this in our review. It is also 
possible that duration of follow-up might affect our sim-
ulations. However, all predictive models employed have 
provided prognostic accuracy data in the longer period of 
time (baseline CHR assessment at 38 months,4 neurocog-
nitive assessment at 48 months,35 combined assessment at 
36  months,22 neuroimaging assessment at 52  months23), 
when most transition to psychosis would have already 
occurred.65 Furthermore, we did not investigate outcomes 
other than psychosis transition, such as functional status,66 
remission,67 or treatment responses,68 which are becoming 
a mainstream focus of CHR research. Different sequen-
tial testing approaches are likely to be needed depending 
on the specific outcome to be predicted. Finally, the cost-
effectiveness of having patients undergo neuroimaging 
testing will need to be established if  there is any likeli-
hood of integrating imaging into routine use.69
Conclusions
The use of a sequential testing approach that improves 
baseline clinical assessments with predictive models from 
different domains, especially biological data may deliver 
high prognostic accuracy for psychosis prediction in sub-
jects undergoing CHR assessment. Although our find-
ings are theoretical and must be validated on original 
data, such probabilistic multimodal and multistep testing 
might help to improve the ability of high-risk services to 
stratify personalized risk profiles.
Supplementary Material
Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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